NCT01742585

A Phase 3 Study of ASP1585 in Chronic Kidney Disease Patients With Hyperphosphatemia Not on Dialysis

ASP1585 Phase 3 Randomized Double Blind Placebo-controlled Study in Chronic Kidney Disease (CKD) Patients With Hyperphosphatemia Not on Dialysis

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 163 (actual)
• Sponsor: Astellas Pharma Inc · Industry
• Sex: All
• Age: 20 Years
• Healthy volunteers: Not accepted

Summary

This is a randomized, double blind, placebo-controlled multi-center study to examine the efficacy and safety of ASP1585 in chronic kidney disease patients with hyperphosphatemia not on dialysis.

Conditions

• Chronic Kidney Disease
• Renal Insufficiency
• Hyperphosphatemia

Interventions

Type	Name	Description
DRUG	ASP1585	oral
DRUG	placebo	oral

Timeline

• Start date: 2012-10-01
• Primary completion: 2014-05-01
• Completion: 2014-05-01
• First posted: 2012-12-05
• Last updated: 2014-07-16

Locations

5 sites across 1 country: Japan